Ask Warren

OliX Pharmaceuticals

226950 · KOSDAQ · ₩226950 · 올릭스

₩96,500▼ ₩800 (0.82%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩2.6B₩3.6B₩4.5B₩2.9B₩6.3B₩977M₩45M₩264M
Operating income−₩14B−₩11B−₩8.5B−₩8.3B−₩5B−₩8.2B−₩7.6B−₩9.4B
Net income−₩1.2B−₩9.8B−₩7.1B₩540M₩4.1B−₩13B−₩30B−₩922M
Net income to shareholders−₩11B−₩9.8B₩15B−₩8.7B−₩9.2B−₩13B−₩12B−₩11B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩274B₩186B₩195B₩187B₩76B₩69B₩71B₩84B
Current assets₩220B₩132B₩141B₩134B₩23B₩15B₩16B₩16B
Cash and equivalents₩111B₩11B₩6.4B₩17B₩7.8B₩8.3B₩3.9B₩3.1B
Total liabilities₩37B₩41B₩45B₩44B₩53B₩43B₩53B₩67B
Current liabilities₩19B₩20B₩21B₩18B₩24B₩21B₩30B₩38B
Borrowings₩20B₩21B₩22B₩23B₩27B₩28B₩38B₩45B
Total equity₩237B₩145B₩150B₩143B₩23B₩26B₩18B₩17B
Shareholders' equity₩237B₩145B₩149B₩142B₩23B₩25B₩18B₩16B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩15B−₩5.7B−₩12B₩3.2B−₩6.3B−₩677M−₩8.2B−₩7.2B
Free cash flow−₩15B−₩5.7B−₩12B₩3.2B−₩6.3B−₩677M−₩8.2B−₩7.2B

Consolidated where available. Amounts in won.

Also known as: OliX Pharmaceuticals / 올릭스 / 226950 / KRX:226950

Source: KRX statistical information